Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset MMSI

Coverage 167,445 Raw stories ingested 22,031 rewritten in CS_CZ • 2 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,373 ETH 4,875 XRP 3,294 SOL 2,999 HYPE 1,765 USDC 1,592

Stocks NVDA 1,796 SPCX 1,459 MU 1,333 MSFT 1,297 AAPL 1,081 TSLA 1,030

Commodities GOLD 558 SILVER 298 OIL 103 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 504 GBPUSD 383 USDCAD 153 USDJPY 146 AUDUSD 100 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 Live Pipeline agents

FMP Stock News Fetch every minute 43s ago
FMP Forex News Fetch every 5 min 43s ago
CoinGecko News Fetch every 5 min 2m ago
FIO Stock News Fetch every 10 min 43s ago
Patria Stock News Fetch every 10 min 43s ago
Editorial rewrite Rewrite every minute running now
Asset sync Assets every 1 hour 9m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-08-24 22:00 16d ago Published 2026-08-24 15:31 16d ago	Merit Medical zvýšil výhled tržeb a zisku Merit Medical zvýšil výhled tržeb i upraveného zisku na akcii pro rok 2026 po silnějších výsledcích za první pololetí. Akcie MMSI se ale dál obchodují za 20,3násobek forward P/E, nad 17,6násobkem v pododvětví. MMSI Merit Medical Systems	FMP Stock News	78
Original source text Key Takeaways Merit Medical raised its 2026 revenue and adjusted earnings outlook after stronger first-half results.Therapeutic products are projected to grow 9.1% from 2025-2028, versus 4.7% for Foundational products.Merit Medical trades at 20.3X forward earnings versus 17.6X for its sub-industry, raising execution pressure. Merit Medical Systems, Inc. (MMSI - Free Report) is showing a better operating trajectory as therapeutic products, recent launches and acquisitions broaden its growth mix. Earnings expectations have also improved, strengthening the fundamental case. The trade-off is valuation. MMSI still carries a premium to its Zacks sub-industry, leaving less room for execution misses even as its growth outlook becomes more favorable. Merit Medical’s Growth Case Is Getting StrongerFor 2026, the Zacks model projects revenues and adjusted earnings per share to increase 7.6% and 11.5%, respectively. The company also raised its 2026 revenue and adjusted earnings outlook after stronger-than-expected first-half results. From 2025 through 2028, revenues and adjusted earnings are projected to post compound annual growth rates of 6.2% and 8.9%, respectively. Therapeutic products are expected to grow at a 9.1% rate, ahead of 4.7% for Foundational products, improving the mix toward faster-growing categories. Image Source: Zacks Investment Research MMSI’s Valuation Leaves Less Room for ErrorMMSI trades at 20.3X forward 12-month earnings compared with 17.6X for its Zacks sub-industry. That premium means further upside depends more heavily on sustained revenue growth, margin execution and continued earnings delivery. The multiple is below MMSI's five-year median of 24.5X, which tempers the valuation concern. Still, the stock is not inexpensive relative to its sub-industry, so stronger fundamentals need to translate into consistent results. Image Source: Zacks Investment Research New MMSI Platforms Add Longer-Term OptionalityThe View Point Medical acquisition added the OneMark Detection Imaging System and OneMark Tissue Markers to Merit Medical's oncology portfolio. Combined with the late-May launch of SCOUT MD, the technologies broaden breast-care localization options across diagnosis and surgery. Endoscopy also gained the Resilience Through-the-Scope Esophageal Stent and C2 CryoBalloon. WRAPSODY remains a multi-year renal-therapy opportunity, although the unchanged $7 million U.S. revenue assumption for 2026 keeps near-term expectations measured. Image Source: Zacks Investment Research Merit Medical Faces Tariff and Execution RisksManagement now expects a 2026 tariff burden of approximately $16 million, or 21 cents per share, up from its prior assumption. Buyer consolidation, distributor dependence in some international markets and currency volatility can also pressure pricing and visibility. Competition remains broad. Boston Scientific Corporation (BSX - Free Report) operates across endoscopy and cardiovascular devices, creating overlap with several Merit Medical procedure areas. Medtronic plc (MDT - Free Report) also reports Cardiovascular and Surgical & Endoscopy businesses, underscoring the need for Merit Medical to support launches while defending established positions. MMSI’s Balance Sheet Supports Strategic FlexibilityMerit Medical ended the second quarter with $448.7 million in cash and cash equivalents and $736.3 million in long-term debt. Its debt-to-capital ratio was 30.5%, below the industry level of 50.5%. Management is building an M&A playbook and broader capital-allocation framework as part of its 2027-2029 strategic planning process. That liquidity can support potential tuck-in acquisitions and product-pipeline priorities, although deployment discipline remains important. MMSI Signals Support a Patient StanceMMSI's improving growth mix, portfolio expansion and stronger earnings outlook support the fundamental case, but the valuation premium and execution risks argue against treating the setup as an easy decision. The balance remains constructive rather than decisive. The stock currently carries a Zacks Rank #3 (Hold). Its Momentum Score of A and VGM Score of B are favorable, while its Value Score of C and Growth Score of C are more middle-of-the-pack. Taken together, the signals support patience while investors watch whether execution can justify the premium. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
	Saved 2026-08-24 19:31 16d ago Published 2026-08-24 15:25 16d ago	Merit Medical zvýšila výhled po silném druhém čtvrtletí Společnost Merit Medical Systems zvýšila výhled na rok 2026 po silném 2. čtvrtletí, kdy tržby vzrostly o 9,5 % na 418,8 mil. USD a upravený zisk na akcii činil 1,19 USD. MMSI Merit Medical Systems	FMP Stock News	78
Original source text Key Takeaways Merit Medical shares rose 22.2% in a month as Q2 revenue and adjusted earnings topped estimates.Therapeutic revenue rose 15%, led by 24% growth in Cardiac Therapies and 29% in Endoscopy.Merit Medical raised 2026 EPS and revenue guidance, while tariff costs are expected near $16 million. Merit Medical Systems, Inc. (MMSI - Free Report) shares have climbed 22.2% in the past month, shifting attention from the size of the rally to whether earnings momentum can support it. The latest quarter provided stronger evidence. Revenue growth accelerated, adjusted earnings beat expectations and management raised its 2026 outlook. Still, the stock now trades above its sub-industry valuation multiple, while tariffs and competitive pressure remain meaningful offsets. Q2 Strength Gives MMSI’s Rally Fundamental SupportSecond-quarter 2026 revenues rose 9.5% year over year to $418.8 million and surpassed the Zacks Consensus Estimate by 3.5%. Adjusted earnings of $1.19 per share increased 18% and beat the consensus mark by 23.9%. Organic revenues increased 9% at constant currency, excluding acquisition contributions and the DualCap divestiture. U.S. revenues increased 11.5% at constant currency, while international revenues rose 4.7%, giving the quarter a broader operating base for the recent share-price advance. Merit Medical’s Therapeutic Mix Is AcceleratingTherapeutic revenues increased 15% on a reported basis, while organic sales advanced 11.7%. Cardiac Therapies and Endoscopy revenues rose 24% and 29%, respectively, making the faster-growing therapeutic portfolio an increasingly important part of the mix. Merit Medical has also broadened its oncology and endoscopy exposure through OneMark and the C2 CryoBalloon. Competition remains substantial. Boston Scientific Corporation (BSX - Free Report) competes across cardiovascular, endoscopy and interventional oncology categories. Medtronic plc (MDT - Free Report) also has broad cardiovascular and endoscopy exposure, raising the importance of product differentiation and commercial execution. MMSI Margin Gains Need a Tariff Reality CheckAdjusted gross margin expanded 260 basis points to 55.8%, supported by pricing, product mix, acquisition performance, manufacturing transfers, automation and lower reliance on air freight. Adjusted operating margin also rose 140 basis points to 22.6%. The tariff-adjusted picture is less dramatic. Excluding tariff refunds, adjusted gross margin was 54.2%, up 98 basis points, while adjusted operating margin was 20.9%, down 22 basis points. Management now expects approximately $16 million of tariff costs in 2026, which could limit further margin progress. MMSI Valuation Tests How Much Upside Is Priced InMMSI trades at 20.3X forward 12-month earnings versus 17.6X for its Zacks sub-industry. That premium suggests investors are already assigning value to the improving growth and earnings outlook. The multiple is still below the stock’s five-year median of 24.5X. That leaves room for a higher valuation if execution stays strong, but the current premium reduces the margin for disappointment after the recent rally. Image Source: Zacks Investment Research Merit Medical’s Estimates Still Point HigherThe Zacks Consensus Estimate for 2026 earnings has moved 5.3% higher in the past four weeks. Management also raised adjusted earnings guidance to $4.25-$4.35 per share from $4.01-$4.15 and lifted its 2026 revenue range to $1.631-$1.643 billion. Estimate momentum is constructive, though risks remain. Consolidation among healthcare buyers can pressure pricing, while management’s 2026 outlook assumes an approximately 80-basis-point benefit to reported revenue growth from foreign exchange. Currency moves can therefore add variability to reported results. Image Source: Zacks Investment Research MMSI Momentum Leads Its Style ProfileThe 22.2% monthly gain now has better fundamental support from organic growth, margin progress and estimate revisions. Valuation and tariff exposure, however, make the next leg of the move more dependent on continued execution. MMSI currently carries a Zacks Rank #3 (Hold), pointing to a balanced short-term view. Its Momentum Score of A is favorable, while its Value Score of C and Growth Score of C keep the style picture mixed. The VGM Score of B adds support, but the Hold rank stops short of signaling the stronger near-term setup associated with top-ranked stocks. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
	Saved 2026-08-15 13:03 25d ago Published 2026-08-15 07:02 26d ago	Merit Medical zvyšuje výhled tržeb a marží Merit Medical Systems připravuje nový dlouhodobý plán, protože těží z růstu tržeb a marží. Firma zároveň zvýšila výhled organických tržeb v konstantní měně na zhruba 7 % až 7,5 %. MMSI Merit Medical Systems	FMP Stock News	86
Original source text Merit Medical Systems NASDAQ: MMSI is preparing its next long-range plan as the medical-device company works through a leadership transition, updates its reporting structure and seeks to build on recent revenue and margin momentum. Speaking at Bank of America’s virtual SMID Cap event, Chief Financial Officer and Treasurer Raul Parra said Merit operates primarily across interventional radiology, cardiac, endoscopy and breast oncology. He described the company’s differentiators as customer focus, product development, acquisitions, vertical integration, global reach and product quality. Parra said the company’s organizational changes began more than five years ago under its “Foundations for Growth” initiative, which was designed in part to prepare for founder Fred Lampropoulos’ retirement. With CEO Martha now in place, Merit is placing greater emphasis on accountability across eight business platforms. Get Merit Medical Systems alerts: “Now that we have Martha here, we’ve dove into the platforms,” Parra said. “Really that’s how we’re going to start running the business.” New Reporting Structure and Long-Range Plan Merit recently reorganized its external reporting into Foundational and Therapeutic product categories. Parra said the change was intended to better align external disclosures with how the company operates internally and to help investors understand the procedures, call points and sources of growth across the business. The Foundational business, which represents about two-thirds of company revenue, includes therapeutic-enabling products such as access, delivery and closure devices. Therapeutics has been growing faster, according to Parra, but the two portfolios remain complementary rather than competing priorities for investment. Therapeutics posted a three-year compound annual growth rate of about 10%, according to Parra. Foundational products grew at roughly 6% over the same period. Parra said both segments have stronger gross-margin characteristics than investors may expect, with Therapeutics retaining the higher gross margin. The company is conducting a deep review of its operations as it develops its next long-range plan, which Parra said could be announced with the fourth-quarter earnings call or potentially earlier. Management is evaluating whether to present the plan through an earnings call or a separate investor event, potentially in Utah or New York. Merit has focused its prior plans on revenue growth, operating-margin expansion and free cash flow. Parra said operating margin expanded about 850 basis points from December 2019 through December 2025, and could reach roughly 950 basis points if the company achieves the high end of its current CGI goals by the end of 2026. While Parra said the company sees further opportunity for margin improvement, he cautioned that management does not expect to repeat the scale of expansion delivered over the past several years. Second-Quarter Momentum and Margin Drivers Parra said Merit’s second-quarter organic growth was supported by a rebound in its OEM business, resolution of a recall-related issue and continued strength in the underlying business. The company found an alternative product for certain customers affected by the recall, he said. Merit raised its organic constant-currency revenue outlook, with Parra describing the midpoint as roughly 7% to 7.5% for the year. He said the company was not seeing a slowdown in procedures, although it continues to account for normal third-quarter seasonality and summer vacation patterns. “The business feels good,” Parra said. “We’re not seeing any slowdown in procedures.” On profitability, Parra said second-quarter gross-margin expansion reflected product mix, pricing discipline, acquisition performance and operational efficiency. He said acquisitions have generally exceeded expectations on gross margin and have met or surpassed revenue expectations. Merit also has shifted more product transportation from air freight to ocean freight where possible. Parra said a tariff refund benefited the quarter, though the company used a portion of that benefit to reinvest in initiatives that had been pulled back when tariffs initially affected the business. M&A Strategy Focused on Existing Platforms Merit intends to continue pursuing acquisitions that deepen its existing positions rather than broadly expanding into new markets, Parra said. Recent deals have supported areas including Oncology, Endoscopy, Cardiac Intervention and Access. He cited the StatSeal acquisition as a Foundational product that can support multiple platforms, while the View Point Medical acquisition added to the Oncology portfolio. The company sees substantial M&A activity in medical technology, according to Parra, as smaller companies face financing and sales-force-building challenges, European businesses navigate Medical Device Regulation requirements, larger companies seek to streamline operations, and private-equity firms look to sell portfolio companies. Merit’s acquisition strategy is centered on tuck-in transactions, and Parra said the company would likely seek to keep leverage below three times in the current interest-rate environment. Deal size is less important than whether an asset fills a portfolio need and can be integrated without compromising long-range operating-margin objectives, he said. Parra said capital allocation, including the relative roles of acquisitions and share repurchases, is part of the company’s strategic-planning process. He also said Merit will evaluate its 2029 convertible debt closer to maturity, potentially considering another convertible issuance or other financing alternatives. “There’s nobody at Merit thinking that, ‘Hey, we’re done,’” Parra said regarding margin expansion and growth opportunities. “The question right now is how much more.” About Merit Medical Systems (NASDAQ:MMSI)Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy. Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Merit Medical Systems Right Now?Before you consider Merit Medical Systems, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list. While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential. Get This Free Report
	Saved 2026-08-15 13:03 25d ago Published 2026-08-15 08:03 26d ago	Merit Medical chystá nový tříletý plán a revizi portfolia Merit Medical Systems připravuje nový tříletý plán a současně přezkoumává portfolio po jednotlivých platformách, aby vybrala menší aktiva mimo své strategické zaměření. MMSI Merit Medical Systems	FMP Stock News	92
Original source text Merit Medical Systems NASDAQ: MMSI is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event. Parra said the company remains “hyper-focused” on executing its current CGI plan and does not want to “drop the football on the one-yard line.” He said the company is working with CEO Martha on the next three-year plan after she spent time visiting company sites and participating in the strategic-planning process. Get Merit Medical Systems alerts: While Parra did not provide new targets, he said Merit is evaluating whether the core metrics used in its past long-range plans remain the right measures for the next plan. Those prior targets included organic revenue growth, operating-margin expansion and cumulative free cash flow. The company has previously presented new plans either in November before a program begins or alongside its fourth-quarter results, though Parra said management is also considering whether to provide the update sooner. Portfolio Review Could Lead to Targeted Changes Merit is reviewing its portfolio platform by platform to determine where it is performing well, where it needs improvement and which assets may not fit the company’s strategic call points, Parra said. He described the process as “strategic and surgical,” rather than one involving large divestitures. The company has assembled businesses across oncology, endoscopy, renal therapies and access through acquisitions, Parra said. While he characterized the portfolio as being in attractive markets and procedures, he said there could be opportunities to prune smaller assets that sit outside Merit's primary call points. Parra cited the company’s divestiture of DualCap as an example of the type of smaller, targeted action management could consider. He said it was too early to determine whether further changes would extend beyond SKU rationalization or involve additional product-line sales. Margin Efforts Remain Broad-Based Parra said Merit has delivered 850 basis points of operating-margin improvement and could approach 950 basis points if it reaches the high end of its current-year guidance. He said the company expects further gains to come from continuing to address a broad range of factors, including pricing, sales mix, new product introductions, acquisitions, manufacturing efficiency, automation, lower-cost production transfers, raw materials, scale and logistics. Rather than relying on a single initiative, Parra said Merit aims to prevent gains in one area from being offset by weaker execution elsewhere. He described the company as being “perpetually” in the seventh inning of margin work: past the heaviest lifting but still able to apply lessons from its prior transformation efforts consistently. On capital allocation, Parra said Merit remains interested in tuck-in acquisitions across its existing platforms, depending on available opportunities. Share repurchases have also been part of management’s strategic-planning discussions, he said, particularly after medtech stocks experienced pressure earlier in the year. Management Points to Guidance for Underlying Growth Merit reported 9% organic growth in the second quarter, its strongest organic-growth result in three years, along with a 22.6% non-GAAP operating margin. Parra said the quarter benefited from an OEM rebound and resolution of a renal recall, but said the result did not surprise management given the underlying performance seen in the first quarter. The company raised its organic-growth outlook to 6.9% to 7.5% and its adjusted earnings-per-share outlook to $4.25 to $4.35. Parra directed investors to the full-year guidance as the best measure of the company’s expected run rate, while adding that Merit has not seen unusual demand weakness or softness in procedure volumes beyond normal seasonal patterns. Parra said hospitals could face pressure from broader reimbursement and funding issues, but Merit’s products generally carry a relatively low average selling price and include products such as access, delivery and closure devices that are required in procedures. He said the company’s broad portfolio, vertical integration and product quality help support its value proposition to health systems. OneMark, Endoscopy and OEM Highlight Growth Areas Executive Vice President of Corporate Finance and Treasury Travis McDougal said the OneMark acquisition expands Merit's participation earlier in the patient pathway, including lower-risk biopsies, and increases the company’s addressable market to roughly $1.3 billion. He said OneMark and the SCOUT MD platform can serve as part of a continuum of care, although management has incorporated some potential cannibalization into its guidance. Parra said the company’s sales force is enthusiastic about having a lower-cost option for cases in which the SCOUT system may not be economically appropriate. He added that the OneMark integration is progressing well. Merit’s endoscopy business grew 29% year over year. Parra said the company does not promise that growth rate will persist, but management is encouraged by the combination of acquired products and new product introductions. McDougal said the segment’s offerings span a patient pathway that includes GERD treatment, Barrett’s esophagus and Merit's legacy endoscopy products. Parra also said second-quarter OEM performance was broad-based, supported by a new customer agreement and product deliveries. Management expects additional deliveries to that customer in the second half and said it remains confident in mid- to high-single-digit growth for the OEM business. On WRAPSODY, Parra reiterated a $7 million target for the current year. After the CGI period, he said management expects WRAPSODY to be discussed within its platform-level business reporting unless it becomes a material growth driver. He said Merit has additional work underway related to the platform but plans to discuss future products closer to approval, when pricing and other commercial dynamics are clearer. About Merit Medical Systems (NASDAQ:MMSI)Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy. Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Merit Medical Systems Right Now?Before you consider Merit Medical Systems, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list. While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates. Get This Free Report
	Saved 2026-07-31 03:54 1mo ago Published 2026-07-30 22:43 1mo ago	Merit Medical Systems uspořádala konferenční hovor k výsledkům za 2. čtvrtletí Merit Medical Systems uspořádala konferenční hovor k výsledkům za 2. čtvrtletí 2026. V dostupném textu ale nepadly žádné konkrétní finanční údaje. MMSI Merit Medical Systems	FMP Stock News	78
Original source text Merit Medical Systems, Inc. (MMSI) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDT Company Participants Martha Aronson - President, CEO & Director Brian Lloyd - Chief Legal Officer & Corporate Secretary Raul Parra - CFO & Treasurer Conference Call Participants Jason Bednar - Piper Sandler & Co., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Lei Huang - Wells Fargo Securities, LLC, Research Division Aidan Lahey - BofA Securities, Research Division Michael Matson - Needham & Company, LLC, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Sam Eiber - BTIG, LLC, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Zachary Day - Canaccord Genuity Corp., Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Welcome to Merit Medical Systems' Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Martha Aronson, Merit Medical Systems' President and Chief Executive Officer. Martha Aronson President, CEO & Director Thank you, operator, and welcome, everyone. I am joined on the call today by Raul Parra, our Chief Financial Officer and Treasurer; and Brian Lloyd, our Chief Legal Officer and Corporate Secretary. Brian, would you mind taking us through the safe harbor statements, please? Brian Lloyd Chief Legal Officer & Corporate Secretary Thanks, Martha. This presentation contains forward-looking statements that receive safe harbor protection under federal securities laws. Although we believe these forward-looking statements are based upon reasonable assumptions, they are subject to risks and uncertainties. The realization of any of these risks or uncertainties as well as extraordinary events or transactions impacting our company could cause actual results to differ materially from the expectations and projections expressed or implied by our forward-looking
	Saved 2026-07-30 23:06 1mo ago Published 2026-07-30 19:00 1mo ago	Merit Medical překonal odhady tržeb i EPS Merit Medical vykázala za čtvrtletí tržby 418,84 mil. USD a EPS 1,19 USD, obojí nad odhady. Tržby meziročně vzrostly o 9,5 %. MMSI Merit Medical Systems	FMP Stock News	78
Original source text Merit Medical (MMSI - Free Report) reported $418.84 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 9.5%. EPS of $1.19 for the same period compares to $1.01 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $404.67 million, representing a surprise of +3.5%. The company delivered an EPS surprise of +23.96%, with the consensus EPS estimate being $0.96. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Merit Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Sales- International: $166.79 million compared to the $165.5 million average estimate based on two analysts. The reported number represents a change of +7.3% year over year.Geographic Sales- United States: $252.05 million compared to the $239.59 million average estimate based on two analysts. The reported number represents a change of +11% year over year.Revenue- Therapeutic: $137.88 million compared to the $132.99 million average estimate based on five analysts.Revenue- Foundational: $280.96 million versus $271.69 million estimated by five analysts on average.View all Key Company Metrics for Merit Medical here>>> Shares of Merit Medical have returned +16.4% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
	Saved 2026-07-09 15:37 2mo ago Published 2026-07-09 10:06 2mo ago	Merit Medical roste díky novým produktům a akvizici Merit Medical Systems rozšiřuje růstové možnosti díky novým produktům a akvizici View Point Medical, která má zhruba ztrojnásobit adresovatelný trh v onkologii. Krátkodobě ale firmu tíží cla, tlak na ceny v Číně a slabší OEM poptávka. MMSI Merit Medical Systems	FMP Stock News	78
Original source text Key Takeaways MMSI is positioned for growth with its strong product portfolio, acquisitions and R&D investments.MMSI launched Resilience and acquired View Point, expanding oncology and endoscopy opportunities.MMSI faces tariff costs, China pricing pressure and OEM demand fluctuations in the near term. Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid product performance and its continued spending on research and development, is expected to contribute further. However, tariffs and trade policy headwinds, and China macro pressure persist. This Zacks Rank #2 (Buy) company’s shares have declined 19.4% in the year-to-date period compared with the industry’s 1.2% drop. However, the S&P 500 has risen 9.5% during the same time frame. The renowned medical device provider has a market capitalization of $4.30 billion. The company projects 8.9% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 12.5% for the past four quarters. Image Source: Zacks Investment Research Let’s delve deeper. MMSI’s Growth DriversStrong Product Portfolio and Strategic Acquisitions: Merit Medical continues to expand its presence across interventional cardiology, radiology, oncology, endoscopy and other minimally invasive procedure markets through a diversified product portfolio and disciplined acquisitions. During the first quarter of 2026, the company launched the Resilience Through-the-Scope Esophageal Stent, which management expects to support long-term growth in its endoscopy business. Merit Medical also acquired View Point Medical, adding the OneMark Detection Imaging System and Tissue Markers to complement its SCOUT platform. Management believes the acquisition expands the addressable procedure opportunity for its oncology business by roughly threefold while providing physicians with additional localization options. Earlier acquisitions, including Biolife and the C2 CryoBalloon technology, continue to strengthen the company's therapeutic portfolio and support long-term growth. Innovation-Driven R&D: Merit Medical continues to invest in research and development to expand its product pipeline and strengthen its competitive position. The company has reorganized its R&D, marketing and commercial teams around eight product platforms, enabling faster product development and closer alignment with physician needs. Supported by approximately 2,200 patents and patent applications, Merit Medical follows a disciplined innovation strategy that prioritizes products with strong commercial potential and attractive returns, positioning the company for sustained long-term growth. WRAPSODY Offers Long-Term Upside: Merit Medical's WRAPSODY Cell-Impermeable Endoprosthesis remains an important long-term growth opportunity within renal therapies. Clinical data continue to demonstrate superior long-term vessel patency compared with conventional angioplasty, supporting broader physician adoption. Management reaffirmed its commercial strategy and expects the product to generate approximately $7 million in revenues in the United States in 2026. While adoption remains in the early stages, continued physician education and expanding clinical evidence position WRAPSODY as a meaningful multi-year growth catalyst. Key Challenges for MMSI StockTariffs and Macroeconomic Uncertainty: Merit Medical continues to operate in an uncertain macroeconomic environment marked by evolving trade policies and geopolitical risks. During the first quarter earnings call, management highlighted tariffs as a significant headwind and expects them to remain a drag on profitability in 2026. While the company has implemented operational initiatives to offset part of the cost pressure, the ultimate impact remains uncertain as it depends on future tariff policies, retaliatory actions and legal developments. Geopolitical disruptions, including those affecting the Middle East, have created temporary shipping delays and higher freight-related costs. Although management described these challenges as manageable, prolonged macroeconomic uncertainty could pressure margins and weigh on earnings growth. OEM and Pricing Headwinds: Merit Medical continues to face near-term pressure in its OEM business, which has experienced demand fluctuations due to inventory destocking, product line transfers and softer international demand, particularly in the Asia-Pacific region. Management expects these issues to be temporary and continues to view the OEM business as a mid- to high-single-digit grower over the long term. However, broader pricing pressure remains a challenge. The company continues to navigate China's volume-based procurement program, which has reduced pricing in recent years and is expected to remain a headwind in 2026. As Merit Medical expands its therapeutic portfolio through acquisitions and new product launches, sustaining growth will require continued innovation and disciplined execution. Estimate TrendMMSI is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has remained stable at $4.07. The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $404.7 million, suggesting a 5.81% rise from the year-ago reported number. The consensus mark for EPS is pegged at 96 cents, implying a 4.9% decline from the prior-year reported figure. Other Stocks to ConsiderSome other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Pacific Biosciences of California (PACB - Free Report) . Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated earnings growth rate of 5.1% for 2026. VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.9%. You can see the complete list of today’s Zacks #1 Rank stocks here. Veracyte’s shares have gained 33.3% against the industry’s 14.2% decline in the year-to-date period. West Pharmaceutical, currently carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. West Pharmaceutical’s shares have gained 28.5% against the industry’s 1.2% decline in the year-to-date period. Pacific Biosciences of California, currently carrying a Zacks Rank #2, has an estimated earnings growth rate of 22.6% for 2026. PACB’s earnings beat estimates in each of the trailing four quarters, the average surprise being 29.8%. Pacific Biosciences’ shares have lost 19.8% compared with the industry’s 14.2% decline in the year-to-date period.